Purpose: Vision significantly affects a person’s quality of life (QOL). This study aims to determine the pharmaco-therapeutic factors influencing it among patients on anti-glaucoma medications. Materials and Methods: A total of 100 patients diagnosed with primary open-angle glaucoma (POAG) on medications for six weeks were included in this cross-sectional study. QOL was assessed using a pre-validated Glaucoma Quality of Life-15 (GQOL-15) Questionnaire. Adverse drug reactions (ADRs) to the anti-glaucoma medications were determined using the pre-validated Comparison of Ophthalmic Medications for Tolerability (COMTOL) checklist. The Chi-square test, Fisher’s exact test and multiple logistic regression analysis were performed to test the statistical significance of the data. A P value of < 0.05 was considered statistically significant. Results: Out of the 100 patients, 76 had good QOL and 24 had poor QOL. Among them, 67 patients were on a single drug, 27 were on a two-drug combination and six were on a three-drug combination for the management of glaucoma. Patients receiving multiple drugs for the management of POAG were associated with poor QOL ( P = 0.006). Out of the other variables tested for association, the presence of ADRs, patients having a positive family history of POAG, patients with a duration of illness of more than three years, hypertensives and diabetics had a statistically significant association with poor QOL. Conclusion: POAG patients on multiple anti-glaucoma medications had poor QOL compared to those on a single drug. Multiple drug combinations caused a greater number of ADRs compared to single drug use. Patients with ADRs had poor QOL. The presence of co-morbidities like diabetes, hypertension and positive family history were associated with poor QOL.
No takes yet. Share an insight, caveat, or question.
Dayanand et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: